An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck

@article{Saloura2014AnOS,
  title={An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck},
  author={Vassiliki Saloura and Ezra E. W. Cohen and Lisa Licitra and Salem Billan and Jos{\'e} Maria Dinis and Steen Lisby and Thomas Christoph Gauler},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2014},
  volume={73},
  pages={1227-1239}
}
Treatment options for patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) are limited. The purpose of this study was to assess the efficacy and safety of zalutumumab in platinum-refractory R/M SCCHN. Patients with platinum-refractory R/M SCCHN were enrolled if they had performance status of 0–2, age ≥18 years and adequate organ function. Patients received weekly infusions of zalutumumab individually titrated to a grade 2 skin rash… CONTINUE READING